A case report describes a seizure two days after a woman abruptly stopped long-term, high-dose zolpidem. Although zolpidem is structurally distinct from benzodiazepines, the paper illustrates why the clinical history of another GABA-related hypnotic matters when evaluating a possible sedative-withdrawal syndrome.
The patient reported more than a year of use, with doses reaching 100 mg on some days, followed by abrupt discontinuation when she could no longer afford the medication. The authors describe a tonic-clonic event, impaired consciousness, post-event confusion, and an abnormal EEG. Their interpretation was a withdrawal seizure associated with the cessation history.
The report documents an individual clinical sequence and a plausible adverse event. It cannot estimate the frequency of seizures at ordinary prescribed doses or demonstrate that women as a group have a particular risk multiplier. A temporal association in a case also does not eliminate every competing explanation.
Reconstruct the actual medication, pattern of escalation, last dose, and onset of symptoms. Do not classify every hypnotic as the same benzodiazepine or infer that absence of current sedation excludes a cessation-related syndrome. The paper’s historical introductory characterization of zolpidem should not be treated as proof that it lacks dependence potential; the case itself concerns that very possibility. It supplies no individualized taper or safe stopping schedule.
This original analysis uses the supplied paper: Zolpidem withdrawal seizure in an Iranian young woman A case presentation. The interpretation above separates the authors’ findings from their implications for evidence review.
Explore related material through this site’s benzodiazepine articles and remimazolam research discussions.